Science

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

lifelinecelltech.com

Mar 7, 2025, 03:20

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Giulia Marvaso, et al. on X:

“In patients with metachronous oligorecurrent hormone-sensitive Prostate Cancer, adding 6 months of ADT to SBRT significantly improved clinical progression-free survival compared to SBRT alone!

Phase 2, randomized trial.
105 patients, single-center (European Institute of Oncology, Milan).
SBRT (30 Gy/3 fx) ± 6 months ADT.”

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Authors: Giulia Marvaso, et al.

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Ankara University cancer Emre Yekedüz European Institute of Oncology fight against cancer Giulia Marvaso Global fight against cancer MedOnc OncoDaily Oncology prostate cancer SBRT

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth